Critical Contrast: Complete Genomics (NASDAQ:GNOM) and Its Rivals

Complete Genomics (NASDAQ: GNOM) is one of 20 public companies in the “Medical Software & Technology Services” industry, but how does it weigh in compared to its rivals? We will compare Complete Genomics to related businesses based on the strength of its analyst recommendations, institutional ownership, valuation, profitability, dividends, risk and earnings.

Valuation & Earnings

This table compares Complete Genomics and its rivals revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Complete Genomics N/A N/A -1.34
Complete Genomics Competitors $413.57 million -$24.55 million 419.72

Complete Genomics’ rivals have higher revenue, but lower earnings than Complete Genomics. Complete Genomics is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares Complete Genomics and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Complete Genomics N/A N/A N/A
Complete Genomics Competitors -14.48% -7.24% 0.20%

Analyst Ratings

This is a summary of recent ratings and price targets for Complete Genomics and its rivals, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Complete Genomics 0 0 0 0 N/A
Complete Genomics Competitors 107 450 848 14 2.54

As a group, “Medical Software & Technology Services” companies have a potential upside of 10.10%. Given Complete Genomics’ rivals higher possible upside, analysts clearly believe Complete Genomics has less favorable growth aspects than its rivals.

Institutional & Insider Ownership

62.7% of shares of all “Medical Software & Technology Services” companies are held by institutional investors. 24.2% of shares of all “Medical Software & Technology Services” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Complete Genomics rivals beat Complete Genomics on 6 of the 8 factors compared.

About Complete Genomics

Complete Genomics, Inc. is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research. Its genome sequencing center combines a high-throughput sample preparation facility, a collection of its high-throughput sequencing instruments and a large- scale data center. Its customers include some of the global academic and government research centers and biopharmaceutical companies. Effective March 18, 2013, BGI-Shenzhen announced that through its wholly-owned subsidiary, Beta Acquisition Corporation, it has completed the acquisition of the Company.

Receive News & Ratings for Complete Genomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Complete Genomics and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Rumor: Milwaukee Brewers Offer Yu Darvish Contract
Rumor: Milwaukee Brewers Offer Yu Darvish Contract
Report: 20-Second Clock and Limit on Mound Visits Rejected by MLBPA
Report: 20-Second Clock and Limit on Mound Visits Rejected by MLBPA
Christian Yelich’s Agent Says Relationship with Marlins is Broken
Christian Yelich’s Agent Says Relationship with Marlins is Broken
Houston Astros Add Starter to Rotation
Houston Astros Add Starter to Rotation
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Justin Morneau Former Star With Twins and AL MVP Retires
Justin Morneau Former Star With Twins and AL MVP Retires


Leave a Reply

 
© 2006-2018 BBNS.